I-gel vs AuraGain for Bronchoscopic Intubation Through SGA
- Conditions
- Airway Management
- Interventions
- Device: Bronchoscopic intubation through AuraGain LMADevice: Bronchoscopic intubation through I-gel SGA
- Registration Number
- NCT04680169
- Lead Sponsor
- Nordsjaellands Hospital
- Brief Summary
This trial compares two different second generation supraglottic airway devices (AuraGain and I-gel) used as a conduit for bronchoscopic tracheal intubation during continuous oxygenation in order tο determine time to successful tracheal intubation and ease of use.
- Detailed Description
A prospective randomized controlled trial in the Department of Anesthesiology, Copenhagen University Hospital Nordsjællands Hospital-Hillerød Denmark. The study is approved by the Ethics Committee, capital region of Denmark. The aim of the study is to compare bronchoscopic tracheal intubation during continuous oxygenation through the AuraGain and I-gel supraglottic airway device. One hundred patients will be randomly allocated into two groups, group A (AuraGain) and group B (I-gel). Study outcomes are time to tracheal intubation confirmed by capnography as well as anesthesiologists reports of ease of use. Twenty-five anesthesiologists participates in this study, and are allocated four patient each. In random order, each physician will perform two bronchoscopic tracheal intubations with each SGA.
In the preoperative setting, a complete anesthetic evaluation will be performed, including a detailed airway assessment determining predictors for difficulties of face mask ventilation, insertion of SGA and tracheal intubation. Participants are scheduled to undergo elective surgery under general anesthesia. Before induction, all patients will be preoxygenated with 100% oxygen. After induction, rocuronium 0.6mg/kg will be used to facilitate neuromuscular blockade. Sufficient face mask ventilation will be performed before intervention.
Group A: AuraGain:
Time is measured from when the anesthesiologist reaches for the AuraGain LMA until the mask is placed and adequate ventilation is confirmed by capnography. The AuraGain LMA will be used as conduit for bronchoscopic intubation during continuous oxygenation, and time is measured until placement of the tracheal tube verified by capnography.
Group B: I-gel:
Time is measured from when the anesthesiologist reaches for the I-gel LMA until the mask is placed and adequate ventilation is confirmed by capnography.The I-gel LMA will be used as conduit for bronchoscopic tracheal intubation during continuous oxygenation, and time is measured until placement of the tracheal tube verified by capnography.
In both groups (A and B) up to two attempts of SGA placement and up to three attempts of tracheal intubation are allowed.
In case of an emerging unpredicted difficult airway and a concurrent unsuccessful SGA placement, the difficult airway algorithm, DAS, UK will be followed. Video- assisted laryngoscopy will be the first option.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
- Patients scheduled for a non-acute ENT, gynaecological, gastrointestinal or orthopaedic surgical procedure for which general anaesthesia including oral intubation with an endotracheal tube will be provided
- Age<18 years
- Inter-incisional distance <30mm
- Pregnant and BMI>40kg/m2
- ASA physical status classification system grade >3
- Earlier laryngeal or pharyngeal surgery
- Increased risk of aspiration (e.g. nasogastric tube inserted, planned Rapid Sequence Induction)
- Informed consent cannot be obtained
- Patients with stridor
- Patients with hypoxemia defines by saturation <90 without oxygen at arrival to the operating room
- Use of oxygen supply at home
- Need of one of the following special endotracheal tubes for scheduled surgery: neural integrity monitor (NIM) electromyogram (EMG) tracheal tubes, wire tubes
- Patients scheduled for any awake approach to secure the airway e.g. awake videolaryngoscopy, awake fiberoptic bronchoscope intubation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group A: Bronchoscopic intubation using AuraGain LMA as conduit Bronchoscopic intubation through AuraGain LMA A group of 50 patients randomly allocated to bronchoscopic intubation using AuraGain Group B: Bronchoscopic intubation with I-gel SGA as conduit Bronchoscopic intubation through I-gel SGA A group of 50 patients randomly allocated to bronchoscopic intubation using I-gel
- Primary Outcome Measures
Name Time Method Total time for airway management Up to study completion, an average of 4 months Total time from reaching the SGA with hands to ended bronchoscopic tracheal intubation confirmed by the end of first curve on capnography
- Secondary Outcome Measures
Name Time Method Time to trans-device tracheal intubation Up to study completion, an average of 4 months time measured from confirmed placement of SGA until successful tracheal intubation confirmed by end of first curve on capnography
Number of attempts needed for correct placement of SGA Up to study completion, an average of 4 months two attempts at correct placement allowed. Attempt is failed if no curve appears on capnography.
Number of attempts needed for correct intubation Up to study completion, an average of 4 months Attempt of bronchoscopic intubation begins when entering aScope in swivel. Attempt is failed if airway is not visualised, if tracheal tube can not be advanced in trachea, if SpO2 is \<85% or if total time exceeds 6 minutes. Three attempts of intubation is allowed.
Time to placement of SGA Up to study completion, an average of 4 months Time measured from reaching SGA with hands to correct placement of SGA confirmed by end of first curve on capnography
Trial Locations
- Locations (1)
Nordsjaellands Hospital
🇩🇰Hillerød, Denmark